Released Jan 29, 2019, after the close
10-K filed Jan 29, 2019, 90 days after period end · 0001654954-19-000854
Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.67M$5.67M derivedno prior Q4 2017 on file+22.5% vs Q3 2018
Net Income$3.34M$3.34M derivedN/M vs Q4 2017+357.3% vs Q3 2018
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,874,421+123.0%
Operating Incomederived$497,442+298.0%
Operating Cash Flowderived$456,907+63.4%
Free Cash Flowderived$392,662−33.1%
Margins · derived
Gross margin33.0%
Operating margin8.8%
Net margin58.9%
What the release said
The release
Same quarter
| Metric | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.67M | — | — | — |
| Net Income | $3.34M | -$547.03K | -$513.32K | $523.45K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR